Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped…
Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped…
Novo Nordisk Escalates Weight-Loss War With Eli Lilly
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) CEO Mike Doustdar is defending the drugmaker’s lawsuit against…
Novo Nordisk CEO Says Obesity Drug Market Won’t Be Winner-Take-All — BigGo Finance
Novo Nordisk (NVO) CEO Mike Doustdar pushed back Wednesday against the prevailing investor narrative that the booming obesity…
Novo Nordisk CEO Concedes Eli Lilly’s Market-Share Gains as Stock Slumps
Photo by BeInCrypto Novo Nordisk’s stock keeps falling even when the news is good, and CEO Mike Doustdar…
Novo Nordisk CFO Knudsen: Oral Wegovy Drives Market Expansion With 80% of Patients New to Obesity Drugs — BigGo Finance
Novo Nordisk delivered what CFO Karsten Munk Knudsen called “one of the bigger guidance hikes we’ve had as…
![[NVO Q2 2026 Earnings Call] Novo Nordisk Raises 2026 Guidance as Wegovy Pill Boom Offsets Pricing Headwinds; 7% Sales Growth, UK Explodes with 300k Patients](https://www.europesays.com/dk/wp-content/uploads/2026/08/aHR0cHM6Ly9pbWcuYmdvLm9uZS9uZXdzLWltYWdlL2Vhcm5pbmdzX2NhcmQvMjAyNi0wOC9VU19OVk9fMjAyNi0wOC0wNV8xNzg1-380x220.jpeg)
[NVO Q2 2026 Earnings Call] Novo Nordisk Raises 2026 Guidance as Wegovy Pill Boom Offsets Pricing Headwinds; 7% Sales Growth, UK Explodes with 300k Patients
Novo Nordisk Raises 2026 Guidance as Wegovy Pill Boom Offsets Pricing Headwinds; 7% Sales Growth, UK Explodes with…
Novo Nordisk raises 2026 forecast after Wegovy pill sales profit
Danish pharmaceuticals giant Novo Nordisk on Tuesday raised its full-year forecast for sales and operating profit on an…
Novo Nordisk moves to launch Wegovy tablet in China
Novo Nordisk plans to seek approval in China for an oral Wegovy weight-loss pill as competition with Eli…
LLY, NVO Stocks Led May’s GLP-1 Rally — But This Smaller ‘Differentiated Player’ Got A Bold 160% Upside Call
Truist assumed coverage on VKTX with a ‘Buy’ rating and an $83 price target, implying an upside of…
Novo Nordisk CEO Discusses Oral Weight-Loss Drugs, Amazon Same-Day Delivery, and Drug Pricing – News and Statistics
May 10, 2026 Novo Nordisk CEO Mike Doustdar discussed the company’s collaboration with Amazon and the expanded availability…
Novo Nordisk partners with OpenAI in weight loss drug race
Novo Nordisk, the maker of popular weight-loss drugs Ozempic and Wegovy, is partnering with OpenAI to deploy the technology…